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http://dx.doi.org/10.1016/j.fjs.2013.Summary Gliosarcomas are bimorphic intra-axial tumors. They rarely involve both the skull
base and ventricles simultaneously. A case of temporal lobe gliosarcoma with significant infra-
temporal fossa and lateral ventricle extension is reported. The patient, an 82-year-old man,
had gradual general weakness and a poor response to speech for 3 weeks. Neurological exam-
ination was unremarkable except for poor awareness and myoclonic jerks. Magnetic resonance
imaging revealed a 72-cm3 right temporal mass with extension into the infratemporal fossa and
the wall of the temporal horn of the lateral ventricle, and consisted of intra-axial and extra-
cranial components with extension to the cavernous sinus, dura, temporal bone, and sphenoid
ridge. The patient underwent a right-sided craniotomy through the orbitozygomatic approach.
Gross total resection was achieved. The histopathological diagnosis was gliosarcoma. Frac-
tional whole-brain radiation and chemotherapy with temozolomide were administered subse-
quently. However, the tumor recurred 1.5 months after his initial treatment, and the survival
time was 9.2 months. In the case of a mass lesion with both intra-axial and extracranial
involvement, the simultaneous involvement of both the skull base and ventricles is highly un-
expected, and gliosarcoma should be included in the differential diagnoses of brain tumors.
The overall treatment and outcome will be difficult to determine if the skull base and ventri-
cles are both involved. An extensive multimodality treatment might be effective in patients
with gliosarcomas according to a review of the literature. The recurrence-free time of gliosar-
coma with skull base extension ranges from 2 months to 12 months, and for gliosarcoma with
ventricular extension, it ranges from 1.5 months to 2 months. The survival time of gliosarcoma
with skull base extension ranges from 7 months to 22 months, and with ventricular extension, itave no conflicts of interest relevant to this article.
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212 S.-J. Liew et al.ranges from 0.33 months to 9.2 months. Gliosarcoma with ventricular involvement might be a
poor prognostic factor, and may help in the prediction of recurrence-free and survival time.
Copyright ª 2013, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Gliosarcomas account for 2e8% of all cases of glioblastoma
multiforme (GBM), depending on the definitions used. They
are primary brain tumors with mixed glial and mesenchymal
components and were first described in 1895 by Heinrich
Stroebe.1 The most common location has been reported to
be the temporal lobe, accounting for 37.5e44% of cases.2e4
However, skull base or ventricular involvement is highly
unexpected. Only five cases of skull base involvement 4e8
and only four cases of ventricular involvement 9e12 have
been reported in the English literature. Moreover, to the
best of our knowledge, the simultaneous involvement of
the skull base and ventricles has not been previously re-
ported in the English literature. In this report, we describe
a case of temporal lobe gliosarcoma with significant infra-
temporal fossa and lateral ventricle extension.
2. Case report
2.1. History and examination
An 82-year-old man presented with a history of old cere-
brovascular accident with left hemiparesis and epilepsy
under Dilantin control for 2 years. He experienced a gradual
general weakness and had a poor response to speech for 3
weeks. His neurological examination showed unremarkable
results except for poor awareness and myoclonic jerks. The
initial Karnofsky performance status score was 50% before
the operation. Magnetic resonance imaging revealed a 72-
cm3 right temporal mass spreading into the infratemporal
fossa (Fig. 1A) via the foramen ovale (Fig. 1D). The tumor
extended to the wall of the temporal horn of the lateral
ventricle (Fig. 1B), cavernous sinus (Fig. 1C), temporal bone
(Fig. 1A), and sphenoid ridge. The lesion’s overall appear-
ance suggested a possible extra-axial origin, with differ-
ential diagnoses including GBM, sarcoma, abscess,
hemangiopericytoma, and metastatic carcinoma.
2.2. Treatment
The patient underwent a right craniotomy through the
orbitozygomatic approach. The tumor consisted of intra-
axial and extracranial components with extension to the
cavernous sinus, dura, temporal bone, and sphenoid ridge.
The tumor had a yellow and reddish-brown color with
an irregular, hard consistency and a relatively well-
circumscribed margin. The frozen-section analysis sug-
gested a spindle-cell malignancy. Extracapsular dissection
was performed after internal debulking of the tumor. Gross
total resection was achieved. The exposed sphenoid sinus
floor and temporal dural defect were repaired with surgisisdural graft (Co. COOK, Cook Biotech Incorporated, West
Lafayette, USA). The patient was subsequently treated
with fractionated whole-brain radiation with a total dose of
50 Gy, followed by 5 days of temozolomide; however, the
tumor recurred 1.5 months after his initial treatment
(Fig. 2). The patient died of pneumonia, and the survival
time was 9.2 months.
2.3. Histological examination
The histopathological diagnosis was consistent with glio-
sarcoma. A gliomatous area of the tumor had the features
of GBM and positive immunoreactivity for GFAP (Fig. 3A),
S100 (Fig. 3B), and vimentin (Fig. 3C). In the sarcomatous
area, there was a spindle-cell proliferation. The genetic
analysis revealed P53 focal positive (Fig. 3D) and MGMT (O6-
methylguanince-DNA methyltransferase) negative (Fig. 3E).3. Discussion
Gliosarcoma is a variant of GBM and diagnosed as a Grade IV
neoplasm (World Health Organization in 2007) that consists
of glial and sarcomatous cell populationsdthe glial
component being that of GBM and the sarcomatous element
having the features of any sarcoma type, but most often
those of the malignant fibrous histiocytoma.2,13 It has been
initially suggested that gliosarcomas should be regarded as
GBM with proliferating endothelium having sarcomatous
features. Vascular smooth muscle and multipotent stem
cells 13 have also been proposed in the context of histo-
genesis. However, data from recent studies have shown
common genetic features for both cell populations,2 and
sarcomatous areas are believed to represent a phenotypic
change in GBM cells instead of a separate malignancy.1 The
incidence of gliosarcoma in published series varies between
2% and 8% of all malignant gliomas.1e3 The most common
location has been reported to be the temporal lobe (in
37.5e44% of the patients).2e4 However, skull base and
ventricular involvement has rarely been reported.
We performed a Medline database search. The keywords
“gliosarcoma”, “skull base”, and “ventricle” were queried
individually and also in association. The included limits were
“English” for the language category. The date of the latest
search was March 2013. There were only five cases of skull
base involvement 4e8 and only four cases of ventricular
involvement 9e12 in the English literature. Moreover, the
simultaneous involvement of the skull base and the ventri-
cles has not been previously reported in the English litera-
ture. We reviewed age, sex, race, location, treatment,
recurrence-free and survival time, and immunohistochem-
ical studies in these cases (Table 1). In the six cases of skull
base involvement group (including our patient), the patients
Figure 1 (A) Postcontrast coronal T1-weighted magnetic resonance imaging (MRI) showing a 72-cm3 right temporal mass with
extension into the infratemporal fossa (arrow) and invading the temporal bone (arrowhead). (B) Postcontrast axial T1-weighted MRI
showing tumor extending to the wall of the temporal horn of the lateral ventricle (arrowheads). (C) Noncontrast axial T2-weighted
MRI showing cavernous sinus invasion (arrow). (D) Postcontrast coronal T1-weighted MRI showing temporal mass spreading into the
infratemporal fossa via the foramen ovale (arrow).
Gliosarcoma with infratemporal fossa extension 213comprised four men and two women with a median age of
61.8 years (range 51e82 years). The locations were all in the
right temporal region. Themedian recurrence-free time was
6.6 months (range 1.5e12 months) after the initial treat-
ment, and the survival time ranged from 7 months to 22
months after the initial treatment. In the ventricular
involvement group (including our patient; Table 1), there
were five patients consisting of four men and one woman
with a median age of 51.2 years (range 25e82 years). The
tumor(s) were all located in the lateral ventricles: three on
the right side, one on the left side, and one on both sides.
After the initial treatment, the recurrence-free time ranged
from 1.5 months to 2 months, and the survival time ranged
from 0.33 months to 9.2 months.
On magnetic resonance images, gliosarcomas appear as
an extra-axial lesion despite the intra-axial origin of the
tumor, as in the present case. The lesions extend to the
infratemporal fossa and the wall of the temporal horn ofthe lateral ventricle, and also involved the cavernous sinus,
temporal bone, and sphenoid ridge. In this case, involve-
ment of the infratemporal fossa and the lateral ventricle
was apparent at the time of initial presentation. The pa-
tient underwent a right craniotomy through the orbitozy-
gomatic approach, which enabled the surgeons to gain wide
access to the high lesion, temporal floor, and cavernous
sinus, and to avoid the temporal muscle, in a short
distance.
The median actuarial survival is 11.5 months for glio-
sarcoma patients, 11.0 months for the control group of
GBM, and 8.1 months for the entire GBM group.1 The me-
dian survival for the gliosarcoma group does not differ
significantly from that of the control GBM group (pZ 0.36)
or of the entire GBM group (pZ 0.16).1 Median survival for
gliosarcoma patients ranges from 6.25 months13 to 8.75
months2 with radiation therapy. Sade et al4 reported a
patient with gliosarcoma with infratemporal fossa
Figure 2 Postcontrast (A) axial and (B) coronal T1-weighted magnetic resonance imaging showing tumor recurrence in the
temporal area (arrowhead) and infratemporal fossa (arrow).
214 S.-J. Liew et al.extension, having completed radiotherapy and chemo-
therapy, who was recurrence-free at the 12-month follow-
up evaluation. Schuss et al 8 reported an unusual case of
gliosarcoma that involved the temporal skull base and the
dura, having extensive multimodality treatment (partial
resection, radiotherapy and chemotherapy with temozo-
lomide, imatinib, hydroxycarbamide, bevacizumab, irino-
tecan). Their report demonstrated that extensive
multimodality treatment might be effective in patients
with gliosarcomas who have poor prognostic factors, for
example, unmethylated MGMT status 8 (12 months of
recurrence-free and 22 months of survival time; Table 2).
However, in our case, the patient was subsequently
treated with fractionated whole-brain radiation, followedFigure 3 Microscopic examination by histochemical stains reve
vimentin. Genetic analysis reveals (D) P53 focal positive a
methyltransferase.by 5 days of temozolomide. The tumor recurred 1.5
months after his initial treatment, and his survival time
was 9.2 months. An analysis of the predominant compo-
nents of the tumor and whether there is ventricular in-
vasion might be helpful to us for prediction of the
prognosis. Gliosarcoma with ventricular involvement
might be a poor prognostic factor. However, because of
the small number of cases in the literature, this needs to
be determined in the future.
In the reviewed six cases of the skull base involvement
group (including our patient), the tumor was all in the right
temporal region. Whether the anatomic structure, any
pathophysiological factor, or other reasons led to this
phenomenon should likewise be explored in the future.als positive immunoreactivity for (A) GFAP, (B) S100, and (C)
nd (E) MGMT negative. MGMT Z O6-methylguanine-DNA
Table 1 Clinical data on gliosarcoma with skull base and/or ventricular extension reported in the literature.
Study, year, ref no Age
(y)
Sex Race Location Surgical resection Radiation, total
dose (Gy)
Chemotherapy Recurrence-
free (mo)
Survival
(mo)
Murphy, 19857 70 Female Caucasian Right temporal base Right anterior
temporal lobectomy
Local radiation
(100)
NM 6 NM
BoRota, 20065 59 Male NM Right fronto-temporal
with infratemporal fossa
extension
Gross-total resection Radiotherapy (NM) NM 6 NM
Sade, 20064 55 Male NM Right temporal base with
infratemporal fossa
extension
Gross-total resection Whole-brain
radiation (NM)
temozolomide (NM) 12 NM
Maeda, 20106 51 Female NM Right temporal base Gross-total resection Local radiation (60) ACNU
temozolomide,
imatinib,
2 7
Schuss, 20118 54 Male Caucasian Right temporal base with
infratemporal fossa
extension
Partial resection Radiotherapy (NM) hydroxycarbamide
bevacizumab,
irinotecan
12 22
Higashino, 200110 29 Male NM Right lateral ventricle Partial resection Whole-brain
radiation (60)
ACNU, carboplatin NM 2.6
Walker, 200612 25 Male NM Left frontal with
intraventricular extension
NM NM NM NM NM
Govindan, 20099 55 Female NM Bilateral lateral ventricle Gross-total resection Non Non NM 0.33
Moiyadi, 201011 65 Male NM Right lateral ventricle Surgical resection Radiotherapy (NM) temozolomide 2 NM
Liew (our patient) 82 Male Asian Right temporal base with
infratemporal fossa and
lateral ventricle extension
Gross-total resection Whole-brain
radiation (50)
temozolomide 1.5 9.2
ACNU Z nimustine; NM Z not mentioned.
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Table 2 Immunohistochemical analysis on gliosarcoma
with skull base and/or ventricular extension reported in the
literature
Study MGMT EGER p53 1p/19q
loss
Murphy,
19857
NM NM NM NM
BoRota,
20065
NM Negative Negative Negative
Sade, 20064 NM Negative Negative Negative
Maeda,
20106
NM NM NM NM
Schuss,
20118
Unmethylated NM Positive NM
Higashino,
200110
NM NM NM NM
Walker,
200612
NM NM NM NM
Govindan,
20099
NM Positive Positive NM
Moiyadi,
201011
NM NM Positive NM
Liew (our
patient)
Unmethylated NM Positive NM
EGFR Z epidermal growth factor receptor; MGMT Z O6-meth-
ylguanine-DNA methyltransferase.
216 S.-J. Liew et al.Thus, we conclude that, with regard to a mass lesion
with both intra-axial and extracranial involvement, the
simultaneous involvement of the skull base and ventricles
must be extremely rare, and gliosarcoma should be
included in the differential diagnosis of brain tumors. The
overall treatment and outcome would be difficult to
determine if the skull base and ventricles are both
involved. However, radical resection combined with
extensive multimodality treatment might be effective in
patients with gliosarcomas and might promise a better
outcome. Ventricular involvement might be a poor prog-
nostic factor, but this should be proved in the future.
Whether ventricular invasion might help in prediction ofrecurrence-free and survival time also needs to be
investigated.References
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